SPEEDX
10.5.2021 22:02:12 CEST | Business Wire | Press release
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, announced it has been awarded up to US $1.8 million from CARB-X, a global non-profit partnership dedicated to supporting research and development to address the rising threat of drug-resistant bacteria. SpeeDx represents the first Australian-based diagnostics company to receive CARB-X funding and a further $1.9 million will be available once the project reaches defined milestones. Funds will be used to develop a rapid test for the combined detection of Chlamydia trachomatis and Neisseria gonorrhoeae , while identifying antimicrobial resistance (AMR) of gonorrhea infections towards common antibiotic treatments. Chlamydia (CT) and gonorrhea (NG) are globally significant sexually transmitted infections with serious health complications if left untreated,1 and AMR NG is an urgent public health threat.2
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510005228/en/
Current antibiotic susceptibility testing methods fail to offer timely and comprehensive susceptibility/resistance information, especially in resource-limited settings. SpeeDx aims to develop an affordable, fast (<60 mins), point-of-care test for the detection of bacteria that cause CT and NG, in addition to determining the susceptibility of NG to three cheap, orally administered, and accessible antibiotics: cefixime, ciprofloxacin, and azithromycin. SpeeDx will utilize their newly patented In Signia™ technology to both assess the presence of active bacterial infection and AMR status. SpeeDx is collaborating with QuantuMDx to port the test onto their Q-POC™ sample to answer qPCR & integrated microarray system - a small battery-powered, simple-to-use device suitable for remote settings.
“We are working closely with QuantuMDx to supply affordable and innovative diagnostics with the goal of significantly improving the standard of care and antibiotic stewardship in STI management,” said Colin Denver, SpeeDx CEO. “This project is an excellent application of our recently developed In Signia technology and the support from CARB-X for this venture will help accelerate this development and extend access in critical need areas.”
Jonathan O’Halloran, Chief Executive, QuantuMDx added: “Antimicrobial resistance is a global public health threat and requires a global response. With rapidly rising rates of AMR, it is no longer good enough to simply provide a pathogen ID, we must also determine what therapeutics the infection is resistant to and which ones the infection are sensitive to. Performing this all within a single assay, as the patient waits, will be transformational. We launch Q-POC™ - our rapid PCR diagnostic system - later this year and we’re looking forward to this, our first commercial collaboration, with SpeeDx.”
About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com
About CARB-X
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global non-profit partnership dedicated to accelerating early development antibacterial R&D to address the rising global threat of drug-resistant bacteria. CARB-X is led by Boston University
and funding is provided by the Biomedical Advanced Research and Development Authority (BARDA),
part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the US Department of Health and Human Services, the Wellcome Trust
, a global charity based in the UK working to improve health globally, Germany’s Federal Ministry of Education and Research (BMBF),
the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (GAMRIF)
, the Bill & Melinda Gates Foundation
, and with in-kind support from National Institute of Allergy and Infectious Diseases (NIAID)
, part of the US National Institutes of Health (NIH). CARB-X is investing up to $480 million from 2016-2022 to support innovative antibiotics and other therapeutics, vaccines, and rapid diagnostics. CARB-X supports the world’s largest and most innovative pipeline of preclinical products against drug-resistant infections. CARB-X is headquartered at Boston University School of Law. carb-x.org/
. Follow us on Twitter @CARB_X.
About QuantuMDx
QuantuMDx Group is an ambitious company with a global vision of empowering the world to control and eradicate disease by making transformative, quality point-of-care diagnostic technologies universally accessible. QuantuMDx has operations and strategic partnerships in the United States, Asia, Australasia, Europe and Africa – keeping it at the forefront of molecular diagnostics. For more information go to: www.quantumdx.com
References
- WHO, News Release: More than 1 million new curable sexually transmitted infections every day, 6 June 2016
- WHO, News Release: Antibiotic-resistant gonorrhoea on the rise, new drugs needed, 7 July 2017
View source version on businesswire.com: https://www.businesswire.com/news/home/20210510005228/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Research Reveals Over Half of Europeans Admit to Looking at a Stranger's Phone Screen in Public – With Nearly a Quarter Doing so out of Sheer Curiosity1.4.2026 08:00:00 CEST | Press release
From dating apps to financial details, respondents report seeing a wide range of highly personal information on others' screens 56% of people admit to having looked at strangers’ phone screens accidentally, whereas 24% have done so out of curiosity. 57% identify public transport as the most likely place to notice someone else's screen. While 48%* feel confident they can keep their phone activity private when using it in crowded places, another 52%** acknowledge it is easy to see someone’s screen who is next to you in a public place without trying to look. 33% say they have seen personal content on a stranger’s phone in public. Some smartphone users who have looked at a stranger’s phone screen in public ignore and continue what they were doing (28%) or look away immediately (27%), but others (7%) admit to continuing to look discreetly. The new Samsung Galaxy S26 Privacy Display1 limits side-angle viewing of your screen to protect your privacy in any setting. As millions of Europeans2 ge
RevolKa Reimagines Antibody Engineering with "RevoAb®"1.4.2026 06:30:00 CEST | Press release
A Same-day Sequence Optimization Service to Elevate Antibody Expression Levels by RevolKa’s advanced AI Protein Engineering Engine RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein®, is pleased to announce the official global launch of RevoAb®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibodyyields. RevoAb®:The Next-Gen AI Antibody Design Since December 2023, RevolKa has provided an antibody optimization services utilizing aiProtein®. The newly launched RevoAb® is a quick intuitive online antibody sequence optimization service that integrates RevolKa’s core technology—the "Refined Naturalness Framework Engineering". RevoAb® is designed to generate antibody framework sequences optimized for improved physicochemical properties, especially protein expression levels, without trade-off of affinity. This allo
Global Beauty Market Grows 10% as AI and E-commerce Reshape Consumer Buying1.4.2026 03:00:00 CEST | Press release
Online sales outpace in-store by 6x as digital-first and AI-influenced commerce accelerates globally NielsenIQ (NYSE:NIQ), a global leader in consumer intelligence, today released its State of Beauty 2026 report, showing the global beauty market grew 10% year-on-year, with E-commerce expanding six times faster than in-store sales. The findings highlight a rapid shift to digital-first, AI-influenced commerce across key global markets. As consumer expectations evolve toward convenience, personalization, and seamless digital experiences, beauty brands are under increasing pressure to adapt. From AI-powered product discovery to social commerce and livestream shopping, the path to purchase is becoming more dynamic—requiring brands to move faster and engage consumers across an increasingly complex ecosystem. Key findings from the State of Beauty 2026 report: Global beauty sales grew 10% year-over-year, driven by strong digital acceleration E-commerce is growing 6x faster than in-store sales,
bet365 Partners with TestMu AI to Accelerate Global Release Velocity with Agentic AI Quality Engineering31.3.2026 19:01:00 CEST | Press release
Streamlines Hillside Technology testing across browsers and mobile devices while supporting rapid expansion into regulated markets. TestMu AI (Formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, today announced that Hillside Technology Limited, the technology powerhouse behind global online gambling leader bet365, has adopted its platform to unify software testing and support hundreds of weekly production releases. The global online gaming industry is currently experiencing a massive shift, with the market projected to exceed $150 billion by 2030. As mobile gaming becomes the primary touchpoint for users, the technical complexity of delivering a seamless, low-latency experience has grown exponentially. For industry giants like bet365, the need to validate software across an infinite matrix of hardware, screen resolutions, and OS versions is a mission-critical requirement. This partnership ensures that, as gaming becomes more mobile-centric, bet36
IFF Secures First Heart Health Claim for Soy Protein in Australia and New Zealand31.3.2026 16:00:00 CEST | Press release
Regulatory milestone opens heart health growth opportunities for food and beverage manufacturers IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and health & biosciences announced today that a new heart health claim for isolated soy protein has been accepted by the Food Standards Australia New Zealand (FSANZ). The approval enables food and beverage manufacturers in Australia and New Zealand to link soy protein consumption with healthy blood cholesterol levels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330523416/en/ First heart health claim approved for soy protein in Australia and New Zealand. “For decades, IFF has invested in the science behind soy protein and its role in supporting cardiovascular health,” said Tony Andrew, vice president of protein solutions for IFF Food Ingredients. “This approved claim validates years of rigorous research and collaboration. With our deep expertise in ing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom